TRT second opinions: Are the 'top 3 mistakes' claims legit?

What's this video probably claiming?

Dr. Alex Tatem, presenting as a TRT specialist offering second-opinion consultations, is almost certainly walking through a familiar list of clinical errors he sees in new patients. Based on the hashtags and caption framing, the "top 3 mistakes" likely include something about over-reliance on total testosterone as the only diagnostic marker, dosing protocols that ignore hematocrit or estradiol management, and possibly dismissing symptoms in men whose labs fall within a technically "normal" range. These are real talking points in hormone optimization circles, and some of them have legitimate clinical grounding. The concern is when a creator blends valid medical critique with implicit promotion of a particular clinic's approach, especially on a platform where the audience skews toward men already convinced they need TRT before they've had a thorough workup.

What does the science actually show?

The diagnosis of male hypogonadism is genuinely more complex than a single lab value. The Endocrine Society guidelines recommend confirming low testosterone with at least two morning fasting samples, measuring both total and free testosterone, and ruling out secondary causes like sleep apnea, obesity, and hyperprolactinemia before initiating therapy. A 2017 analysis by Travison et al. in the Journal of Clinical Endocrinology and Metabolism found significant inter-laboratory variation in testosterone assays, meaning a result of 280 ng/dL at one lab might read as 320 ng/dL at another. The TRAVERSE trial (Lincoff et al., 2023, NEJM), which followed over 5,000 men with hypogonadism for a mean of 33 months, confirmed non-inferiority of TRT for major cardiovascular events but also documented a higher incidence of atrial fibrillation, pulmonary embolism, and acute kidney injury in the testosterone group. That nuance rarely makes it into a 60-second TikTok.

Where does the social media noise diverge from clinical reality?

The "second opinion" framing is clever marketing. It positions the creator as a corrective authority without requiring him to say anything explicitly wrong. The problem is the implied message: that most prescribers are undertreating men or using outdated protocols. Some are. But the data on TRT initiation trends suggests the opposite problem is more common. A 2017 study by Baillargeon et al. in JAMA Internal Medicine found that roughly 25% of men starting TRT had no testosterone measurement in the prior 12 months, and another large cohort showed many initiating therapy without documented hypogonadism symptoms at all. The "mistakes" narrative maps neatly onto a sales funnel for telehealth TRT platforms, which have financial incentives to prescribe. That does not automatically make the clinical content wrong, but it should make you read the fine print on whatever platform is hosting this creator.

What should you actually know?

If you're considering TRT after watching content like this, a few things are worth holding onto. Free testosterone measurement matters more than total testosterone in men with obesity or thyroid dysfunction, because sex hormone binding globulin levels distort the total number. Estradiol management during TRT is a real clinical consideration, though the aggressive use of aromatase inhibitors like anastrozole is not evidence-based for most men and carries its own risks, including bone density loss. Hematocrit above 54% is a genuine concern requiring dose adjustment or therapeutic phlebotomy per Endocrine Society guidance. The 2018 Testosterone Trials (Snyder et al., NEJM) showed modest benefits in sexual function and mood in men over 65 with confirmed low testosterone, but effects on energy and cognition were less consistent. A good second opinion is valuable. A second opinion from someone with a financial interest in your prescription is something else.